Anti-SMAD3 pS423 pS425 (RABBIT) Antibody
Cat# 600-401-919S
Size : 25ul
Brand : Rockland Immunochemicals
Contact local distributor :
Phone : +1 850 650 7790
Background
This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. Smad3 (also known as Mothers against decapentaplegic homolog 3 Mothers against DPP homolog 3, Mad3, hMAD-3, JV15-2 or hSMAD3) is a transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinase. These activators exert diverse effects on a wide array of cellular processes. The Smad proteins mediate much of the signaling responses induced by the TGF-b superfamily. Briefly, activated type I receptor phosphorylates receptor-activated Smads (R-Smads) at their c-terminal two extreme serines in the SSXS motif, e.g. Smad2 and Smad3 proteins in the TGF-b pathway, or Smad1, Smad5 or Smad8 in the BMP pathway. Then the phosphorylated R-Smad translocated into nucleus, where they regulate transcription of target genes. Based on microarray and animal model experiments, Smad3 accounts for at least 80% of all TGF-b-mediated response.
Specifications for SMAD3 phospho S423/phospho S425 Antibody
Product Details
Anti-SMAD3 pS423 pS425 (RABBIT) Antibody - 600-401-919
rabbit anti-SMAD3 pS423pS425 antibody, SMAD-3, SMAD 3, mothers against decapentaplegic homolog 3 antibody, MAD homolog 3, Mothers against DPP homolog 3, SMAD family member 3, MADH3, MADH 3, JV15-2, nothing
Rabbit
Polyclonal
IgG
Target Details
SMAD3 - View All SMAD3 Products
Human
Phosphorylation
Conjugated Peptide
Anti-SMAD3 pS423pS425 antibody was prepared from whole rabbit serum produced by repeated immunizations with a dual phosphorylated synthetic peptide corresponding to a c-terminal region with Serine 423 and Serine 425 of human SMAD3 protein.
This affinity-purified antibody is directed against the phosphorylated form of human Smad3 protein at the pS423 and pS425 residues. The product was affinity purified from monospecific antiserum by immunoaffinity purification. Antiserum was first purified against the phosphorylated form of the immunizing peptide. The resultant affinity purified antibody was then cross adsorbed against the non-phosphorylated form of the immunizing peptide. Reactivity occurs against human Smad3 pS423 and pS425 protein and the antibody is specific for the phosphorylated form of the protein. Reactivity with non-phosphorylated human Smad3 is minimal by ELISA and western blot. Expect reactivity against phosphorylated Smad1 and Smad5. Negligible reactivity is seen against other phosphorylated Smad family members. A BLAST analysis was used to suggest cross reactivity with Smad3 from human, Xenopus laevis, Xenopus tropicalis, zebrafish, rat, mouse, swine, bovine and chicken based on 100% sequence homology with the immunogen. Reactivity against homologues from other sources is not known.
NCBI - 5174513
UniProtKB - P84022
GeneID - 4088
Application Details
ELISA, IHC, WB
IF, IP, Multiplex - View References
This affinity purified antibody has been tested for use in ELISA, immunohistochemistry, and western blot. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 48 kDa in size corresponding to phosphorylated Smad3 protein by western blotting in the appropriate stimulated tissue or cell lysate or extract. Less than 0.2% reactivity is observed against the non-phosphorylated form of the immunizing peptide. This antibody is phospho specific for dual phosphorylated pS423 and pS425 of Smad3. Stimulation with 2 ng/ml TGF-beta for 1 hour is suggested.
Formulation
1.16 mg/ml by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Dry Ice
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
References (34)
El-Gazzar, A et al. (2022). SMAD3 mutation in LDS3 causes bone fragility by impairing the TGF-β pathway and enhancing osteoclastogenesis. Bone Reports
Applications
WB, IB, PCA PubMed
Iida R et al. (2022). Deficiency of M-LP/Mpv17L leads to development of β-cell hyperplasia and improved glucose tolerance via activation of the Wnt and TGF-β pathways. Biochim Biophys Acta Mol Basis Dis.
Applications
Undefined PubMed
Wang W et al. (2022). SARS‐CoV‐2 N Protein Induces Acute Kidney Injury via Smad3‐Dependent G1 Cell Cycle Arrest Mechanism. Adv Sci (Weinh).
Applications
IF, Confocal Microscopy; IHC, ICC, Histology PubMed
Tang PCT et al. (2022). Smad3 Promotes Cancer‐Associated Fibroblasts Generation via Macrophage–Myofibroblast Transition. Adv Sci (Weinh).
Applications
WB, IB, PCA PubMed
Pinkaew D et al. (2022). Fortilin interacts with TGF-β1 and prevents TGF-β receptor activation. Commun Biol.
Applications
WB, IB, PCA PubMed
Bosch-Queralt M et al. (2021). Diet-dependent regulation of TGFβ impairs reparative innate immune responses after demyelination. Nat Metab.
Applications
IHC, ICC, Histology PubMed
Tamura Y et al. (2021). Anti-pyroptotic function of TGF-β is suppressed by a synthetic dsRNA analogue in triple negative breast cancer cells. Mol Oncol.
Applications
IHC, ICC, Histology PubMed
Dong L et al. (2021). Deletion of Smad3 protects against diabetic myocardiopathy in db/db mice. J Cell Mol Med.
Applications
IHC, ICC, Histology PubMed
Takagaki Y et al. (2020). Endothelial autophagy deficiency induces IL6-dependent endothelial mesenchymal transition and organ fibrosis. Autophagy.
Applications
WB, IB, PCA PubMed
Hutchinson LD et al. (2020). Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses. Cell Death Dis.
Applications
WB, IB, PCA PubMed
Kang H et al. (2020). Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway. J Exp Med.
Applications
WB, IB, PCA PubMed
Navarro R et al. (2020). TGF‐β‐induced IGFBP‐3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion. Mol Oncol.
Applications
WB, IB, PCA PubMed
Ni J et al. (2020). Dual deficiency of angiotensin‐converting enzyme‐2 and Mas receptor enhances angiotensin II‐induced hypertension and hypertensive nephropathy. J Cell Mol Med.
Applications
IHC, ICC, Histology PubMed
Kim IY et al. (2020). Deletion of Akt1 Promotes Kidney Fibrosis in a Murine Model of Unilateral Ureteral Obstruction. Biomed Res Int.
Applications
WB, IB, PCA PubMed
Yang F et al. (2019). Inhibition of dipeptidyl peptidase-4 accelerates epithelial–mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis. Cancer Res.
Applications
IF, Confocal Microscopy; WB, IB, PCA; Multiplex Assay PubMed
Gao R et al. (2019). βklotho is essential for the anti‐endothelial mesenchymal transition effects of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline. FEBS Open Bio.
Applications
WB, IB, PCA PubMed
Wei X et al. (2019). Spatially restricted stromal Wnt signaling restrains prostate epithelial progenitor growth through direct and indirect mechanisms. Cell Stem Cell.
Applications
Undefined PubMed
Stappenbeck F et al. (2019). Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling. Cells.
Applications
WB, IB, PCA PubMed
Feng et al. (2018). TGF-β Mediates Renal Fibrosis via the Smad3-Erbb4-IR Long Noncoding RNA Axis. Molecular Therapy
Applications
IHC, ICC, Histology PubMed
Li et al. (2018). Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight
Applications
IHC, ICC, Histology; WB, IB, PCA PubMed
Tang et al. (2018). Generation of Smurf2 Conditional Knockout Mice. International Journal of Biological Sciences
Applications
WB, IB, PCA PubMed
Chung et al. (2018). TGF-β promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight
Applications
IF, Confocal Microscopy; WB, IB, PCA; Multiplex Assay PubMed
Huang H et al. (2018). Lethal (3) malignant brain tumor-like 2 (L3MBTL2) protein protects against kidney injury by inhibiting the DNA damage–p53–apoptosis pathway in renal tubular cells. Kidney Int.
Applications
WB, IB, PCA PubMed
Liu L et al. (2018). Neuronal transforming growth factor beta signaling via SMAD3 contributes to pain in animal models of chronic pancreatitis. Gastroenterology.
Applications
IHC, ICC, Histology PubMed
tang et al. (2017). Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway. Journal of Biological Chemistry
Applications
WB, IB, PCA PubMed
Li et al. (2017). FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway. Cell Death & Disease
Applications
WB, IB, PCA PubMed
Tripathi V, Sixt KM, Gao S, et al (2016). Direct Regulation of Alternative Splicing by SMAD3 through PCBP1 Is Essential to the Tumor-Promoting Role of TGF-β. Mol Cell.
Applications
IP, Co-IP; WB, IB, PCA PubMed
Yamada, C et al. (2016). TGF-β in jaw tumor fluids induces RANKL expression in stromal fibroblasts. International Journal of Oncology
Applications
WB, IB, PCA; IHC, ICC, Histology PubMed
Luo et al. (2015). A novel profibrotic mechanism mediated by TGFβ-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. The Journal of Pathology
Applications
WB, IB, PCA PubMed
Subathra et al. (2015). Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells. American Journal of Physiology Renal Physiology
Applications
WB, IB, PCA PubMed
Herhaus L. et al. (2013). OTUB1 enhances TGFβ signalling by inhibiting the ubiquitylation and degradation of active SMAD2/3. Nat Commun.
Applications
WB, IB, PCA PubMed
Kawamura I et al. (2012). SnoN suppresses maturation of chondrocytes by mediating signal cross-talk between transforming growth factor-β and bone morphogenetic protein pathways. J Biol Chem.
Applications
IHC, ICC, Histology PubMed
Coffman JA et al. (2009). Oral–aboral axis specification in the sea urchin embryo: III. Role of mitochondrial redox signaling via H2O2. Dev Biol.
Applications
IF, Confocal Microscopy PubMed
Yamashita M. et al. (2008). TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell.
Applications
IP, Co-IP; WB, IB, PCA PubMed
Related Protocols
Adherent Cell Lysis Protocol
ELISA Protocol
Fluorescent Western Blotting Protocol
Heat-induced Antigen Retrieval Protocol
Histone Immunoblotting Protocol
Immunocytochemistry (ICC) Protocol
Immunofluorescence (IF) Protocol
Immunohistochemistry (IHC) Protocol
Immunoprecipitation (IP) Protocol
In-Cell Western (ICW) Protocol
IP-WB with TrueBlot® Protocol
Multi-Lysate Western Blotting Protocol
Nuclear & Cytoplasmic Extract Protocol
Protease-induced Antigen Retrieval Protocol
Sandwich ELISA Protocol for Collagen
Staining Paraffin Sections by PAP Procedure
Suspension Cultured Cell Lysis Protocol
Western Blotting (WB) Protocol
Certificate of Analysis Lookup
Disclaimer
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Related products to: SMAD3 phospho S423/phospho S425 Antibody
Ready-To-Use SMAD3 Antibody 600-401-E70-RTU SMAD3 Antibody 600-401-E70 SMAD3 Antibody 600-401-973 SMAD3 Antibody 600-401-920 SMAD3 phospho T179 Antibody 600-401-C48 Related Resources
GFP Antibodies: A Comprehensive Guide
Articles
View Article
Custom Recombinant Antibodies (rAbs)
Learn More
Custom Antibody Production
Learn More